Group 1 - The company has successfully executed the Advance 2025 strategic plan, achieving significant transformation and operational streamlining [2] - Margin expansion was realized, increasing from 13% to 16%, alongside a strengthened balance sheet with 10 consecutive quarters of positive free cash flow [2] - The specialty food ingredient business experienced a volume/mix growth of 4%, and the previously loss-making algae omega-3 business was turned into a profitable nutrition platform [2] Group 2 - The Advance 2025 plan delivered a top line CAGR of 9% and an EBITDA growth of 8% [2] - The company divested its low-growth emulsifier business and invested in new capacity, particularly a lactic acid plant in Thailand, to drive future value [2] - The upcoming Bright 2030 strategic plan is expected to build on the achievements of Advance 2025 [3]

Corbion Capital Markets Day Summary Company Overview - **Company**: Corbion (OTCPK:CSNV.Y) - **Event**: 2025 Capital Markets Day - **Date**: November 20, 2025 - **Key Focus**: Transition from Advance 2025 to Bright 2030 strategic plan Key Achievements and Financial Performance - **Advance 2025 Achievements**: - Margin expansion from 13% to 16% [1] - 10 consecutive quarters of positive free cash flow [1] - Top-line CAGR of 9% and EBITDA growth of 8% [2] - Specialty food and green business volume mix grew by 4% [1] - **Bright 2030 Goals**: - Targeting 3%-6% annual top-line sales growth for 2026-2028 [2] - Adjusted EBITDA margin goal of 18% [2] - Cumulative free cash flow target of EUR 270 million [2] Strategic Focus Areas - **Natural Preservation and Nutrition**: - Emphasis on clean label and natural ingredients due to consumer demand [3][4] - Regulatory pressures favoring sustainable food solutions [4] - Focus on functional foods due to aging population and health awareness [4] - **Market Dynamics**: - Addressable market for food preservation is nearly $3.5 billion, with a combined opportunity of $7 billion when including shelf life extension [6] - Nutrition market, including omega-3s, is also valued at nearly $7 billion, growing at 2%-6% per annum [7] Innovation and Technology - **Fermentation Technology**: - Unique ability to scale from lab to industrial production [9] - New lactic acid plant in Thailand enhances sustainability and cost efficiency [10][16] - Circular manufacturing process reduces carbon footprint [13] - **Product Portfolio**: - Focus on natural antimicrobials, antioxidants, and acidification solutions [27][28] - Successful replacement of synthetic ingredients with natural alternatives [30] Sustainability Commitment - **Climate Goals**: - Aim for net-zero emissions across the value chain by 2050 [21] - 99% of raw materials are verified deforestation-free [21] - Natural preservation solutions help prevent over 10 million tons of food waste annually [19] Financial Outlook - **Medium-Term Financial Targets**: - Organic sales growth of 3%-6% per annum [51] - Adjusted EBITDA margin improvement to around 18% by 2028 [51] - Cumulative free cash flow of around EUR 270 million over the next three years [51] - **Capital Allocation**: - Balanced approach focusing on organic growth and shareholder returns [58] - Anticipated CapEx around 6% of sales [62] Conclusion - Corbion is well-positioned to capitalize on market trends towards natural ingredients and sustainability, with a strong focus on innovation and operational efficiency. The Bright 2030 strategy aims to enhance growth and profitability while maintaining a commitment to environmental responsibility and consumer health.

BRIGHT 2030 Strategy & Financial Targets - The company aims for organic sales growth of 3-6% per annum from 2026-2028[6, 100, 123, 145] - The company targets an adjusted EBITDA margin of approximately 18% in 2028[6, 100, 123, 145] - The company projects a cumulative free cash flow of approximately €270 million over three years (2026-2028)[6, 100, 123, 145] - The company is targeting a double-digit percentage growth in EPS (Earnings Per Share) per annum from 2026-2028[123, 143, 145] - The company aims for a ROCE (Return on Capital Employed) of approximately 13% by 2028[123] Business Segment Performance & Growth - Food sales reached €769 million in 2024[41, 42, 126] - Nutrition sales reached €157 million in 2024[59, 60, 126] - Biomedical Polymers sales reached €55 million in 2024, with a target of €125 million by 2030[89, 94] - The company's natural food preservation market share is 25%[44] - The company projects to grow the Food business to €1 billion by 2030, representing approximately 4% CAGR[53, 54] - The company projects over €100 million additional Nutrition sales in the coming 5 years, reaching €275 million by 2030, representing approximately 10% CAGR[82] Sustainability & Operations - The company sources 98% of its raw materials from renewable sources[27, 33] - The company aims for a 42% reduction in Scope 1 & 2 emissions and a 25% reduction in Scope 3 emissions by 2030[29]